Based on key financial metrics such as the price-to-sales ratio, shareholder yield and the price-earnings ratio, the following 4 stocks made the list for top value stocks in the Biotechnology & Medical Research industry. Those looking for value stocks to add to their portfolio may want to use this list as a starting point for further investment research.

Why Focus on Undervalued Biotechnology & Medical Research Stocks?

Value investors seek to buy stocks at a discount to their intrinsic value. Long-term returns show that such strategies are advantageous. Value stocks, as a group, tend to outperform growth stocks over extended periods of time. Typically, value investors perform financial analysis of numerous metrics, don’t follow the herd and are long-term investors.

AAII’s A+ Investor Value Grade is derived from a stock’s Value Score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

What Goes Into AAII’s Value Grade?

Stock evaluation requires access to huge amounts of data as well as the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movement. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors with that task.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades for more than just value. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others. Some stocks may even have null values for certain metrics like the price-earnings ratio or the price-to-book ratio but not others. An example of this would be a company with losses instead of profits or a negative book value because of heavy borrowing. Negative earnings or book value result in non-meaningful ratios that are left blank or null.

Click the button below to learn more about A+ Investor and subscribe today.

4 Undervalued Biotechnology & Medical Research Stocks

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued stocks in the Biotechnology & Medical Research industry for Wednesday, August 28, 2024. Let’s take a closer look at their individual scores to see how they measure up against each other and the Biotechnology & Medical Research industry median.

The Value Grade is assigned based on how each stock’s composite valuation compares to all other stocks.

The process for assigning grades starts with each variable for a given stock. The percentile rankings for all valid ratios that a stock has are calculated. So, for instance, a stock could have a price-to-book ranking in the 43rd percentile, a price-earnings ranking in the 67th percentile, a price-to-sales ranking in the 23rd percentile, etc. Then, those rankings are averaged for each stock. (A minimum of two valid variables are required, though all six will be used if available.)

Once the average of the individual variables is calculated, that average is ranked against all stocks. Put another way, each stock’s composite valuation is compared to all other stocks. These ranks are then sorted into quintiles from the cheapest 20% (a grade of A) to the most expensive 20% (a grade of F).

As always, we recommend that you conduct proper due diligence and research before investing in any security. We also suggest that investors utilize numerous grades, not just value, when it comes to deciding whether a company is a good fit for their allocation needs.

Bellerophon Therapeutics Inc’s Value Grade

Value Grade:

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company’s focus is to develop its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical development for the therapeutic delivery of inhaled nitric oxide. It is also developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD), PH-Sarcoidosis, PH-chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other pulmonary hypertension conditions. The Company’s subsidiaries include Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Bellerophon Therapeutics Inc has a Value Score of 82, which is considered to be undervalued.

When you look at Bellerophon Therapeutics Inc’s price-to-sales ratio at 0.08 compared to the industry median at 7.23, this company has a lower price relative to revenue compared to its peers. This could make Bellerophon Therapeutics Inc’s stock more attractive for value investors.

Shareholder yield is the sum of a stock’s dividend yield (paid over previous 12 months minus special dividends) and the percentage of net share buybacks over the previous 12 months. Bellerophon Therapeutics Inc’s shareholder yield is lower than its industry median ratio of (17.45%). Value investors may look for an attractive shareholder yield because it can be a powerful tool for identifying if the company has a good management team.

As one of the most common value metrics, the price-to-book ratio evaluates a company’s current market price relative to its book value. Bellerophon Therapeutics Inc’s price-to-book ratio is lower than its industry median ratio of 2.07. This could make Bellerophon Therapeutics Inc more attractive to investors looking for a new addition to their portfolio.

Dominari Holdings Inc’s Value Grade

Value Grade:

Dominari Holdings Inc. is a holding company. The Company, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading and asset management. It operates through its wholly owned subsidiaries, including Dominari Financial Inc. (Dominari Financial) and Dominari Securities LLC (Dominari Securities). Dominari Securities offers and plans to offer a range of broker-dealer and registered investment adviser services. Its services include wealth management, investment banking, sales and trading, asset management and insurance products. Dominari Securities provides a comprehensive array of financial services to high-net-worth individuals and families, corporate executives, and public and private businesses. Dominari Securities also provides full-service brokerage, wealth planning and margin lending services. Dominari Securities’ investment banking division provides strategic advisory services and capital markets products to middle market businesses.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Dominari Holdings Inc has a Value Score of 63, which is considered to be undervalued.

Dominari Holdings Inc’s price-to-book ratio is higher than its peers. This could make Dominari Holdings Inc less attractive for value investors when compared to the industry median at 2.07.

You can read more about Dominari Holdings Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

MEI Pharma Inc’s Value Grade

Value Grade:

MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) and B-cell malignancies as a single-agent, and in combination with the B-cell lymphoma 2 (BCL) inhibitor venetoclax (marketed as Venclexta) in patients with AML. ME-344 is a novel mitochondrial inhibitor drug candidate that demonstrates tumor selective activity in pre-clinical studies. It targets the OXPHOS pathway involved in the production of adenosine triphosphate (ATP).

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

MEI Pharma Inc has a Value Score of 98, which is considered to be undervalued.

MEI Pharma Inc’s price-earnings ratio is 0.8 compared to the industry median at 33.1. This means that it has a lower price relative to its earnings compared to its peers. This makes MEI Pharma Inc more attractive for value investors.

MEI Pharma Inc’s price-to-book ratio is higher than its peers. This could make MEI Pharma Inc less attractive for value investors when compared to the industry median at 2.07.

You can read more about MEI Pharma Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Synaptogenix Inc’s Value Grade

Value Grade:

Synaptogenix, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders. The Company is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. It has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in AD.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Synaptogenix Inc has a Value Score of 70, which is considered to be undervalued.

Synaptogenix Inc’s price-to-book ratio is higher than its peers. This could make Synaptogenix Inc less attractive for value investors when compared to the industry median at 2.07.

You can read more about Synaptogenix Inc’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.

Other Biotechnology & Medical Research Stock Grades

Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate revisions and quality—on the A+ Stock Grades Screener.

Also, if you want full access to all of AAII’s premium services, you can subscribe to one convenient bundled plan called AAII Platinum where you can try out A+ Investor, AAII Dividend Investing, the Stock Superstars Report, Growth Investing and VMQ Stocks. With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about Biotechnology & Medical Research stocks as well as other industrys.

Choosing Which of the 4 Best Biotechnology & Medical Research Stocks Is Right for You

Choosing which value stocks to invest in will ultimately depend on your individual goals and allocation; however, comparing similar value stocks in the same industry can help you analyze which might be better investments for you in the long run. So, let’s take a look at the Value Grade for all of our stocks.

• Bellerophon Therapeutics Inc stock has a Value Grade of A.
• Dominari Holdings Inc stock has a Value Grade of B.
• MEI Pharma Inc stock has a Value Grade of A.
• Synaptogenix Inc stock has a Value Grade of B.

Now that you have a bit more background about each of the 4 undervalued stocks in the Biotechnology & Medical Research industry as well as their overall grades, it’s time for you to conduct additional research to see if these could fit your portfolio needs based on your goals and risk tolerance. AAII can help you figure out both and identify which investments align with what works best for you.

We do so through a program of education that teaches you to invest for yourself and become an effective manager of your own wealth—no more relying on others for your financial independence. You can rely on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis that makes you a better investor.

A+ Investor adds to that qualitative teaching by giving you a powerful data suite that helps you whittle down investment decisions to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

Additional Resources About Biotechnology & Medical Research Stocks

Want to learn more about Biotechnology & Medical Research stocks to see if they could be the right investment for you? Check out some additional resources and articles to help you on your financial journey.

• 4 Undervalued Biotechnology & Medical Research Stocks for Wednesday, August 28
• 5 Undervalued Biotechnology & Medical Research Stocks for Tuesday, August 27
• Why Alnylam Pharmaceuticals, Inc.’s (ALNY) Stock Is Up 4.13%
• Why C4 Therapeutics Inc’s (CCCC) Stock Is Down 7.22%

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith and we accept no liability for any errors or omissions. The full disclaimer can be read here.